CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
Afatinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04640870
NCT04640870N/ACompleted
CompareCT.gov

An Observational Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib in Real-world Clinical Set-tings in Greece

Hellenic Cooperative Oncology Group·observational·Posted Nov 23, 2020·Updated Dec 23, 2020

In Brief

An observational study evaluating Afatinib for Non Small Cell Lung Cancer and 2 related conditions. Completed, enrolled 59 participants.

Detailed Summary

This is an observational, non-interventional, single-country, multi center, retrospective cohort study, based on real world data collection, of patients with locally advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation-positive Non-Small Cell Lung Cancer (NSCLC) who had been treated with Afatinib at any line.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon Small Cell Lung Cancer, EGF-R Positive Non-Small Cell Lung Cancer, EGFR Gene Mutation
Countries--
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 23, 2020
Enrollment StartMar 15, 2015
Primary CompletionMar 1, 2020
Study CompletionMay 1, 2020
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 5.6 years ago

Interventions

Afatinibdrug

Treatment with Afatinib, any line, in metastatic, EGFR mutated patients with NSCLC